260 related articles for article (PubMed ID: 30773851)
1. Retinoblastoma mutation predicts poor outcomes in advanced non small cell lung cancer.
Bhateja P; Chiu M; Wildey G; Lipka MB; Fu P; Yang MCL; Ardeshir-Larijani F; Sharma N; Dowlati A
Cancer Med; 2019 Apr; 8(4):1459-1466. PubMed ID: 30773851
[TBL] [Abstract][Full Text] [Related]
2. Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.
Offin M; Chan JM; Tenet M; Rizvi HA; Shen R; Riely GJ; Rekhtman N; Daneshbod Y; Quintanal-Villalonga A; Penson A; Hellmann MD; Arcila ME; Ladanyi M; Pe'er D; Kris MG; Rudin CM; Yu HA
J Thorac Oncol; 2019 Oct; 14(10):1784-1793. PubMed ID: 31228622
[TBL] [Abstract][Full Text] [Related]
3. EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes.
Marcoux N; Gettinger SN; O'Kane G; Arbour KC; Neal JW; Husain H; Evans TL; Brahmer JR; Muzikansky A; Bonomi PD; Del Prete S; Wurtz A; Farago AF; Dias-Santagata D; Mino-Kenudson M; Reckamp KL; Yu HA; Wakelee HA; Shepherd FA; Piotrowska Z; Sequist LV
J Clin Oncol; 2019 Feb; 37(4):278-285. PubMed ID: 30550363
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological and genomic comparisons between different histologic components in combined small cell lung cancer and non-small cell lung cancer.
Lin MW; Su KY; Su TJ; Chang CC; Lin JW; Lee YH; Yu SL; Chen JS; Hsieh MS
Lung Cancer; 2018 Nov; 125():282-290. PubMed ID: 30429033
[TBL] [Abstract][Full Text] [Related]
5. Genetic profiling-based prognostic prediction of patients with advanced small-cell lung cancer in large scale analysis.
Udagawa H; Umemura S; Murakami I; Mimaki S; Makinoshima H; Ishii G; Miyoshi T; Kirita K; Matsumoto S; Yoh K; Niho S; Tsuchihara K; Goto K
Lung Cancer; 2018 Dec; 126():182-188. PubMed ID: 30527185
[TBL] [Abstract][Full Text] [Related]
6. Clinical correlation of extensive-stage small-cell lung cancer genomics.
Dowlati A; Lipka MB; McColl K; Dabir S; Behtaj M; Kresak A; Miron A; Yang M; Sharma N; Fu P; Wildey G
Ann Oncol; 2016 Apr; 27(4):642-7. PubMed ID: 26802149
[TBL] [Abstract][Full Text] [Related]
7. Transformation or tumor heterogeneity: Mutations in EGFR, SOX2, TP53, and RB1 persist in the histological rapid conversion from lung adenocarcinoma to small-cell lung cancer.
Hao L; Chen H; Wang L; Zhou H; Zhang Z; Han J; Hou J; Zhu Y; Zhang H; Wang Q
Thorac Cancer; 2023 Apr; 14(11):1036-1041. PubMed ID: 36810856
[TBL] [Abstract][Full Text] [Related]
8. Transformation to small cell lung cancer is irrespective of EGFR and accelerated by SMAD4-mediated ASCL1 transcription independently of RB1 in non-small cell lung cancer.
Ding X; Shi MX; Liu D; Cao JX; Zhang KX; Zhang RD; Zhang LP; Ai KX; Su B; Zhang J
Cell Commun Signal; 2024 Jan; 22(1):45. PubMed ID: 38233864
[TBL] [Abstract][Full Text] [Related]
9. Targeted Inhibition of the E3 Ligase SCF
Zhao H; Iqbal NJ; Sukrithan V; Nicholas C; Xue Y; Yu C; Locker J; Zou J; Schwartz EL; Zhu L
Cancer Res; 2020 Jun; 80(11):2355-2367. PubMed ID: 32265224
[TBL] [Abstract][Full Text] [Related]
10. Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?
Ou SI; Lee TK; Young L; Fernandez-Rocha MY; Pavlick D; Schrock AB; Zhu VW; Milliken J; Ali SM; Gitlitz BJ
Lung Cancer; 2017 Apr; 106():110-114. PubMed ID: 28285684
[TBL] [Abstract][Full Text] [Related]
11. Cells Lacking the
Oser MG; Fonseca R; Chakraborty AA; Brough R; Spektor A; Jennings RB; Flaifel A; Novak JS; Gulati A; Buss E; Younger ST; McBrayer SK; Cowley GS; Bonal DM; Nguyen QD; Brulle-Soumare L; Taylor P; Cairo S; Ryan CJ; Pease EJ; Maratea K; Travers J; Root DE; Signoretti S; Pellman D; Ashton S; Lord CJ; Barry ST; Kaelin WG
Cancer Discov; 2019 Feb; 9(2):230-247. PubMed ID: 30373918
[TBL] [Abstract][Full Text] [Related]
12. Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D.
Simbolo M; Mafficini A; Sikora KO; Fassan M; Barbi S; Corbo V; Mastracci L; Rusev B; Grillo F; Vicentini C; Ferrara R; Pilotto S; Davini F; Pelosi G; Lawlor RT; Chilosi M; Tortora G; Bria E; Fontanini G; Volante M; Scarpa A
J Pathol; 2017 Mar; 241(4):488-500. PubMed ID: 27873319
[TBL] [Abstract][Full Text] [Related]
13. Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC.
Kim Y; Lee B; Shim JH; Lee SH; Park WY; Choi YL; Sun JM; Ahn JS; Ahn MJ; Park K
J Thorac Oncol; 2019 Feb; 14(2):193-202. PubMed ID: 30391576
[TBL] [Abstract][Full Text] [Related]
14. Multi-region exome sequencing reveals the intratumoral heterogeneity of surgically resected small cell lung cancer.
Zhou H; Hu Y; Luo R; Zhao Y; Pan H; Ji L; Zhou T; Zhang L; Long H; Fu J; Wen Z; Wang S; Wang X; Lin P; Yang H; Wang J; Song M; Yi X; Yang L; Xia X; Guan Y; Fang W; Yang Y; Hong S; Huang Y; Li P; Zhang Y; Zhou N
Nat Commun; 2021 Sep; 12(1):5431. PubMed ID: 34521849
[TBL] [Abstract][Full Text] [Related]
15. Genotyping of RB1 status identifies two distinct subtypes in EGFR-mutant lung cancers with SCLC transformation.
Huang J; Zhang SL; Zhang C; Huang W; Zhang Z; Chen YQ; Su JW; Yan HH; Chen HJ; Yang JJ; Wang J; Wu YL
Clin Transl Med; 2024 May; 14(5):e1683. PubMed ID: 38736106
[No Abstract] [Full Text] [Related]
16. Immune Checkpoint Blockade Outcome in Small-Cell Lung Cancer and Its Relationship With Retinoblastoma Mutation Status and Function.
Dowlati A; Abbas A; Chan T; Henick B; Wang X; Doshi P; Fu P; Patel J; Kuo F; Chang H; Balli D
JCO Precis Oncol; 2022 Aug; 6():e2200257. PubMed ID: 36044718
[TBL] [Abstract][Full Text] [Related]
17. RB1 loss induced small cell lung cancer transformation as acquired resistance to pembrolizumab in an advanced NSCLC patient.
Arakawa S; Yoshida T; Shirasawa M; Takayanagi D; Yagishita S; Motoi N; Ohe Y
Lung Cancer; 2021 Jan; 151():101-103. PubMed ID: 33279272
[No Abstract] [Full Text] [Related]
18. RB1 polymorphism contributes to the efficacy of platinum-taxanes in advanced squamous cell lung cancer.
Liu D; Xu W; Zhang ZW; Qian J; Zheng H; Zhang J; Su B
Asian Pac J Cancer Prev; 2015; 16(2):775-81. PubMed ID: 25684524
[TBL] [Abstract][Full Text] [Related]
19. KMT2D Mutation Is Associated With Poor Prognosis in Non-Small-Cell Lung Cancer.
Ardeshir-Larijani F; Bhateja P; Lipka MB; Sharma N; Fu P; Dowlati A
Clin Lung Cancer; 2018 Jul; 19(4):e489-e501. PubMed ID: 29627316
[TBL] [Abstract][Full Text] [Related]
20. Differential regulation and synthetic lethality of exclusive RB1 and CDKN2A mutations in lung cancer.
Kim N; Song M; Kim S; Seo Y; Kim Y; Yoon S
Int J Oncol; 2016 Jan; 48(1):367-75. PubMed ID: 26647789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
